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Abstract Design: A prospective case series.
Aim: On a search for an effective, safe, cheap, and available sclerosing agent, the present study
aimed to evaluate the effectiveness and the safety of tranexamic acid as a chemical agent for pleu-
rodesis in malignant pleural effusion (MPE).
Methods: Tube thoracostomy was done for drainage of pleural ﬂuid. Once the tube in the pleural
space drains 150 ml per day or less with fully expanded lung, infusion of pleurodesis solution con-
taining 2000 mg of tranexamic acid [four ampoules of tranexamic acid each is 5 ml (100 mg/ml),
mixed with 50 ml of normal saline] was done through the intercostal tube. The tube was then
clamped immediately and left in the pleural cavity for 2 h. Follow up chest radiographs were done
every 24 h till removal of the tube which was done when daily drainage is 100 ml or less. Chest X ray
(CXR) was done after three months to judge success (no ﬂuid re-accumulation). The results were
statistically analyzed and tabulated.
Results: Sixteen patients with MPE were included in this study, 9 (56%) males and 7 (44%)
females with age ranging from 45 to 70 with mean age ± SD= 57.5 ± 8.3 years. The follow up
after 3 months showed a complete response rate (no ﬂuid re-accumulation on CXR) of 75%
(12 n 16), a partial response rate (asymptomatic ﬂuid re-accumulation on CXR) of 12.5% (2 n 16)
and a no response rate (symptomatic ﬂuid re-accumulation on CXR that required pleural drainage)
of 12.5% (2 n 16).
Abbreviations: MPE, malignant pleural effusion; CXR, chest X ray.
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Conclusion: Tranexamic acid was found to be an effective, safe, cheap, and available sclerosing
agent for pleurodesis in recurrent malignant pleural effusion.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of The Egyptian Society of Chest
Diseases and Tuberculosis. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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588 E.A. Mohammed et al.Introduction and aim of the work
Pleurodesis is a palliative therapy for symptomatic, recurren
malignant pleural effusions (MPE). The success of pleurodesi
depends on the tumor burden, pleural ﬂuid pH, and the efﬁ
cacy of the selected sclerosing agent [1].
On a search for an effective, safe, cheap, and available scle
rosing agent, the present study aimed to evaluate the effective
ness and the safety of tranexamic acid as a chemical agent fo
pleurodesis.
Methods
This study was a prospective case series, conducted on twent
patients with recurrent pleural effusion admitted at Ches
Department, Benha University (Benha city, Egypt) from
February 2011 to February 2012.
Patients with recurrent pleural effusion and completel
expanded lung were included in this work. Patients with unsuc
cessful lung re-expansion after tube thoracostomy, Bleedin
tendency or terminal disease were excluded.
All patients were subjected to full history taking wit
general and local examination, chest radiograph (postero
anterior and lateral views), chest C.T scan (was done t
detect pleural thickening, loculations or underlying lesio
as masses), pelvi-abdominal sonography (to detect abdomi
nal causes of effusion or associated ascites), laborator
investigations (including liver function tests, kidney functio
tests and coagulation proﬁle), pleural biopsy (with Abram’
needle or thoracoscopic pleural biopsy for histopathologica
examination).
Tube thoracostomy was done for drainage of pleural ﬂuid
Once the tube in the pleural space drains 150 ml per day or les
with fully expanded lung which is conﬁrmed on chest X ray [2
infusion of pleurodesis solution containing 2000 mg of tranex
amic acid [four ampoules of tranexamic acid each i
5 ml)100 mg/ml), mixed with 50 ml of normal saline] was don
through the intercostal tube. The tube was then clampe
immediately and left in the pleural cavity for 2 h during whic
the patient was turned to the supine, prone, right and left lat
eral decubitus and sitting position so that pleurodesis solutio
came in contact with all pleural surfaces. The patient was kep
in each position for 30 min. After 2 h, the chest tube wa
unclamped. Follow up chest radiographs were done ever
24 h till removal of the tube which was done when daily drai
nage is 100 ml or less.
The patients were discharged and followed up after thre
months using plain CXR to judge success of the procedur
(no ﬂuid re-accumulation):
1. Complete response (success) means no radiographic evi
dence of ﬂuid re-accumulation was noted on follow up.2. Partial response means re-accumulation of ﬂuid that did
not produce symptoms and did not require repeat pleural
drainage of any sort on follow up.
3. No response means ﬂuid re-accumulation that produced
symptoms and required pleural drainage on follow up.
The results were statistically analyzed and tabulated using
PSS program statistical program (version 14, SPSS Inc.,
SA: Chicago, IL).
esults
ixteen patients with malignant pleural effusion were included
n this study. There were 12 (60%) males and 8 (40%) females.
heir age ranged from 45 to 70 with mean age ± SD=
7.5 ± 8.3 years (Tables 1 and 2).
As regards the side of effusion 9 (56%) cases were left sided
leural effusion and 7 (44%) cases were right sided. The main
resenting symptom was dyspnea in 8 (50%) cases and chest
ain in 8 (50%) cases (all 8 cases had Mesothelioma).
As regards methods of diagnosis, 8 n 16 (50%) were
iagnosed by thoracoscopic pleural biopsy, 4 n 16 (25%) were
iagnosed by closed pleural biopsy (using Abram’s needle) and
n 16 (25%) were diagnosed by positive cytological examina-
ion for malignant cells in pleural ﬂuid. The histopathological
ypes of these malignant effusions were Mesothelioma in 8 n 16
50%) and Metastatic Adenocarcinoma in 8 n 16 (50%) cases
Tables 1 and 2).
Regarding the outcome and the response to tranexamic
cid pleurodesis 12 (75%) showed complete response, 2
12.5%) showed partial response and other 2 (12.5%) cases
howed no response (Tables 1 and 2). The time for removal
f the chest tube after injecting tranexamic acid ranged from
to 7 days (mean ± SD= 4.6 ± 1.25 days).
The failed pleurodesis (no response) in the 2 cases who had
alignant mesothelioma was caused by thickening of the
leura seen by Thoracoscopy (Fig. 1 shows one of them) and
ailure of the lung to expand.
As regards complications, no signiﬁcant complications were
etected after tranexamic acid pleurodesis.
The cost of tranexamic acid in Egypt is about 21 LE (less
han 3 US dollars) per pack of six 5 ml ampoules (100 mg
er 1 ml).
iscussion
n a search for an effective, safe, cheap, and available scleros-
ng agent with least side effects, the present study aimed to
valuate the effectiveness and the safety of tranexamic acid
s a chemical agent for pleurodesis.
Sixteen patients with MPE were included in this study, 9
56%) males and 7 (44%) females. Their age ranged from 45
to 70 with mean age ± SD= 57.5 ± 8.3 years (Tables 1 and
2).
As regards the side of effusion 9 (56%) cases were left sided
pleural effusion and 7 (44%) cases were right. In a study by
Shalabi [3], 8 (40%) cases were left sided, 11 (55%) cases were
right sided pleural effusion and one case (5%) presented with
bilateral pleural effusion, massive on the left and mild on the
right side. In EL-Bouhi et al. [4] study 4 (20%) cases were left
sided pleural effusion and 16 (80%) cases were right side.
The main presenting symptom in this study was dyspnea in
the 8 Adenocarcinoma cases (50%) and chest pain in the 8
Mesothelioma cases. Shalabi [3] reported that 15 (75%) cases
presented with dyspnea and 5 (25%) cases presented with chest
pain (all cases with chest pain had Mesothelioma). Antman [5]
stated that the main presenting symptom in malignant
mesothelioma is chest pain in 60% to 70% and dyspnea and
cough in 25% and 20% respectively.
Regarding the method by which diagnosis was made in this
study, thoracoscopic pleural biopsy made the diagnosis in
8 n 16 (50%) cases, closed pleural biopsy (using Abram’s nee-
dle) in 4 n 16 (25%) cases and positive cytological examination
for malignant cells in other 4 n 16 (25%) cases. The histopatho-
logical types of the malignant effusions were Mesothelioma in
8 n 16 (50%) and Metastatic Adenocarcinoma in 8 n 16 (50%)
cases. In another study [3] the histopathological types of these
malignant effusions were Mesothelioma in 3 n 15 (20%) and
Adenocarcinoma in 12 n 15 (80%) cases. In a study by EL-
Bouhi et al. [4] 12 (60%) patients had malignant pleural effu-
sion, 4 (20%) had hepatic hydrothorax and other 4 (20%)
cases had renal failure.
All patients were subjected to injection of pleurodesis solu-
tion of 50 ml of normal saline with four ampoules of tranex-
amic acid each is 5 ml)100 mg/ml(infused through intercostal
tube. This coincided with the study of Badawy and Eisa [6]
Table 1 Data of cases studied regarding age, sex, clinical ﬁndings and outcome after tranexamic acid pleurodesis.
Case no Age** Sex Main presenting symptom Pathology Diagnosis method Outcome
1 64 Male Chest pain Mesothelioma Pleural biopsy Partial response
2 57 Male Dyspnea Adenocarcinoma* Pleural biopsy Complete response
3 68 Female Dyspnea Adenocarcinoma* Cytology Complete response
4 53 Female Chest pain Mesothelioma Pleural biopsy Complete response
5 59 Female Dyspnea Adenocarcinoma* Pleural biopsy Complete response
6 63 Male Dyspnea Adenocarcinoma* Pleural biopsy Complete response
7 46 Male Dyspnea Adenocarcinoma* Cytology Complete response
8 57 Female Chest pain Mesothelioma Pleural biopsy Complete response
9 48 Male Dyspnea Adenocarcinoma* Pleural biopsy Complete response
10 68 Female Chest pain Mesothelioma Pleural biopsy Complete response
11 49 Male Dyspnea Adenocarcinoma* Cytology Complete response
12 63 Female Chest pain Mesothelioma Pleural biopsy Complete response
13 49 Male Chest pain Mesothelioma Pleural biopsy No response
14 45 Female Dyspnea Adenocarcinoma* Cytology Complete response
15 70 Male Chest pain Mesothelioma Pleural biopsy Partial response
16 62 Male Chest pain Mesothelioma Pleural biopsy Partial response
* Metastatic Adenocarcinoma.
** Mean age ± SD= 57.5 ± 8.3 years.
Table 2 Data of cases studied regarding age, sex, clinical
ﬁndings and outcome after tranexamic acid pleurodesis in
number and percent.
No. of patients %
Sex
Male 9 56
Female 7 44
Eﬀusion side
Left 9 56
Right 7 44
Main presenting symptom
Dyspnea 8 50
Chest pain 8 50
Method of diagnosis
Thoracoscopic biopsy 8 50
Closed pleural biopsy 4 25
Cytology 4 25
Pathology of malignant eﬀusions
Mesothelioma 8 50
Metastatic Adenocarcinoma 8 50
Response to tranexamic acid pleurodesis
Complete response 12 75
Partial response 2 12.5
No response 2 12.5
Figure 1 Marked pleural thickening and inﬁltration in a case of
malignant pleural mesothelioma.
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in which he used 50 ml of normal saline solution with four
ampoules of tranexamic acid each is 5 ml)100 mg/ml(was
infused through intercostal tube. This differs from the study
of Shalabi [3] in which Pleurodesis was done after thoraco-
centesis (without intercostal tube placement) by an injection
of 25 ml of tranexamic acid (containing 2500 mg), and from
EL-Bouhi et al.’s [4] study who used a high dose of tranexamic
acid which is 10 ampoules of tranexamic acid each
5 ml)100 mg/ml) infused through intercostal tube.
Regarding outcome and the response to tranexamic acid
pleurodesis in this study, 12 (75%) showed complete response,
2 (12.5%) showed partial response and other 2 (12.5%) cases
showed no response. The time for removal of the chest tube
after injecting tranexamic acid ranged from 3 to 7 days
(mean ± SD4.5 ± 1.25 days). The failed pleurodesis in the 2
cases who had malignant mesothelioma resulted from thicken-
ing of the pleura seen by Thoracoscopy (Fig. 1 shows one of
the cases) and failure of the lung to expand.
So the complete success rate in this study, using tranexamic
acid pleurodesis in malignant effusions was 75% (12 out of 16
cases) which agrees with that reported by Badawy and Eisa [6]
(73.5% success rate), but lower than the results reported by
Shalabi [3] (success rate of 84.2%) and EL-Bouhi et al. [4] (suc-
cess rate 90%). The much higher success rate in El-Bouhi et al.
[4] may be due to a higher dose of tranexamic acid used
(5000 mg) and the exclusion of partial success cases in this
study (2 cases = extra 12.5%).
The results in this study were slightly higher than the results
of other studies that used other chemical agents for pleurode-
sis, for example the results obtained by Zimmer et al [7] using
tetracycline for pleurodesis with a success rate of 65%, and are
higher than the results achieved by Martı´nez et al [8] using
bleomycin for pleurodesis with a success rate of 60–80%.
In a report by Essam et al. [9] comparing bleomycin or
tranexamic acid alone versus a combination of both concluded
that the combination of bleomycin (1 Unit/kg, with maximum
of 40 Unit) and tranexamic acid (30 mg/kg, with maximum of
2 gm) for pleurodesis was more efﬁcient (65%) than each alone
(35% and 27%, respectively).
Ramadan et al. [10] studied different pleurodesis agents in
malignant pleural effusion and found that efﬁcacy was 70%
for bleomycin, 80% for doxycycline and 80% for povidone
iodine, while 5-ﬂuorouracil had the lowest success rate (50%).
Mohammed and Hassan [11] studied the oral form of dox-
ycycline and reported that 72.7% (16 out of 22 patients with
malignant pleural effusion) had successful pleurodesis and
Chest tube duration averaged 4.2 ± 2.6 days with com-
plications included chest pain in 10 patients (45.5%), fever in
2 (9.1%) patients, and pain and fever in 5 patients (22.7%).
Shouman et al. [12] studied Chemical pleurodesis for malig-
nant pleural effusion in 75 patients and reported that using
Tetracycline, talc slurry, iodopovidone and bleomycin,
resulted in an insigniﬁcantly different success rates of 80%,
80%, 66.6%.73.3%, at 30 days and, 66.6%, 73.3%, 60%,
66.6%, at 60 days respectively. Chest tubes were removed after
an average of 7.2 ± 1.4 days for tetracycline, 7 ± 0.8 days for
talc slurry, 7.6 ± 0.9 days for iodopovidone and 6.4 ±
1.5 days for bleomycin which did not differ signiﬁcantly.
Chest pain was more common in the tetracycline group, dysp-
nea was more common in the talc group, and fever was more
common in the iodopovidone group.
In a report [13] that reviewed the literature for pleurodesis
in the treatment of malignant pleural effusions between 1966
and 1992 concluded that the total success rate was 64%.
[Corynebacterium parvum was 76%, Doxycycline was 72%,
Tetracycline was 67%, Bleomycin was 54% and Talc was
93% (the highest).]
As regards complications, no signiﬁcant complications were
detected after tranexamic acid pleurodesis. Others [3,4,6] found
no complications after using tranexamic acid for pleurodesis.
The complications which were noted with different scle-
rosant agents are chest pain, fever and cough [14].
Tetracycline was the most common agent used in the past,
but it is no longer available now with an average success rate
of 65% and reported complication as chest pain, fever and
cough [7].
Werebe et al. [15] reported that talc is the most commonly
used substance for pleurodesis which is highly effective and
widely available with an average success rate of 90% but
may cause systemic embolization in animal and ARDS in
9% of patients after talc pleurodesis.
Martı´nez et al. [8] reported that bleomycin is the most
widely administered antineoplastic agent with a success rate
of 60–80%, but with complications including chest pain, fever,
and nausea and is costly.
Fry et al. [16] reported that non chemical pleurodesis,
thoracostomy with pleurectomy and de-cortication are effec-
tive but these operations have a mortality of 10% and a high
morbidity as prolonged air leaks.
Spiegler et al. [17] reported complete response to pleurode-
sis in 48%, a partial response in 31%, and 21% did not
respond to pleurodesis. Chemical pleurodesis was performed
as an outpatient procedure (using talc slurry or bleomycin).
The follow up was done after 4 weeks of the procedure and
judging success using same criteria we used in our study.
Conclusion
Tranexamic acid was found to be an effective, safe, cheap, and
available sclerosing agent for pleurodesis in recurrent malig-
nant pleural effusion.
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